BIOGAIA Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

SECOND QUARTER 2026 Net sales amounted to SEK 440.9 million (404.7), an increase of SEK 36.2 million, an increase excluding currency effects of 12% (9% including currency effects). Net sales in the Pediatrics segment amounted to SEK 331.7 million (310.1), an increase excluding currency effects of 9% (7% including currency effects). Net sales in the Adult Health segment amounted to SEK 106.6 million (89.8), an increase excluding currency effects of 23% (19% including currency effects). Operating expenses amounted to SEK 188.8 million (185.5), an increase of SEK 3.3 million (2%)....

BioGaia's (NASDAQ: BIOG) financial report for the second quarter of 2026 will be published at approximately 8:00 AM CEST on July 17, 2026. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST. To join the audiocast with teleconference and ask a...

BioGaia AB's subsidiary, Biogaia New Sciences AB, is expanding its BioGaia[®] Skincare portfolio with two new products and an updated design across the full range. The expanded skincare line reinforces BioGaia's ambition to apply its microbiome expertise beyond gut health, oral health and immune health, supporting healthy and balanced skin from the earliest stages of life. Building on the success of BioGaia[®] Probiotic Ointment, the skincare range is extended with Gentle Balm to Milk Wash and Soothing Face & Body Lotion, creating a complete skincare routine for babies and children with...

The Annual General Meeting of BioGaia AB (publ) was held on 7 May 2026 at 4.00 pm at Klara Konferens & Happynings, Klarabergsviadukten 90, Stockholm, at which the shareholders passed the resolutions set out below. · Adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet. · Discharge from liability for the Board members and the CEO. · A dividend of SEK 1.64 per share plus an extra dividend of SEK 2.36 per share, resulting in a total dividend of SEK 4.00 per share, with a record date of 11 May 2026, and a grant of SEK...

We are proud to launch BioGaia[®] Protectis[®] Plus, our next-generation patented probiotic baby drops. BioGaia[®] Protectis[®] Plus has additive probiotic effects and was developed to bring further digestive relief to babies and improve quality of life for families worldwide. Across the globe one out of five families wake up every night to put their colicky baby to sleep, affecting the family's quality of life. BioGaia launched the revolutionary and scientifically proven BioGaia[®] Protectis[®] baby drops in 2004, a product that offered and continues to offer relief to babies and their...

FIRST QUARTER 2026 Net sales amounted to SEK 372.6 million (366.3), an increase of SEK 6.3 million, an increase excluding currency effects of 15% (2% including currency effects). Net sales in the Pediatrics segment amounted to SEK 272.2 million (269.9), an increase excluding currency effects of 13% (1% including currency effects). Net sales in the Adult Health segment amounted to SEK 98.3 million (94.6), an increase excluding currency effects of 18% (4% including currency effects). Operating expenses amounted to SEK 165.6 million (171.2), a decrease of SEK 5.6 million (3%). There...

BioGaia's (NASDAQ: BIOG) financial report for the first quarter of 2026 will be published at approximately 8:00 AM CEST on May 7, 2026. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST. To join the audiocast with teleconference and ask a...

Researchers at BioGaia have published new scientific findings in the journal Food and Bioprocess Technology, demonstrating that BioGaia's patented LongevityGuard[®] technology significantly improves the stability and shelf life of probiotics. The paper, entitled “A Novel Approach Using a Protective Desiccant Increases Shelf Life and Reduces Moisture in Oil Suspensions of Freeze-Dried Limosilactobacillus reuteri”, presents data showing how moisture control is critical to maintaining probiotic viability. The study confirms that LongevityGuard[®], a proprietary moisture-control technology...

BioGaia AB (publ) (the “Company”) will hold its Annual General Meeting at 4 p.m. on 7 May 2026, at Klara Konferens & Happynings på Klara Strand, Klarabergsviadukten 90, in Stockholm. The doors will be opened for registration at 3:30 p.m. Right to participate In order to participate in the Annual General Meeting (AGM), shareholders must be recorded in the register of shareholders maintained by Euroclear Sweden AB relating to the circumstances on 28 April 2026 and must provide notice of participation to the Company no later than 30 April 2026. Notification can be made by mail to BioGaia...

The BioGaia (NASDAQ: BIOG) Annual and Sustainability Report 2025, including Corporate Governance Report 2025, and the Remuneration Report 2025 in Swedish as well as an English translation are now available to download from the BioGaia website: https://www.biogaiagroup.com/investors/reports-and-presentations/annual-reports The Swedish Annual and Sustainability Report 2025 is also available on BioGaia's website in European Single Electronic Format (ESEF).   Follow us: Subscribe to BioGaia press releases here (https://www.biogaiagroup.com/newsroom/subscribe-to-press-releases) LinkedIn...

We are proud to announce the publication of a 10-year follow-up study of our probiotic strain, Limosilactobacillus reuteri (L. reuteri) Protectis[Ò][ ]also known as L. reuteri DSM 17938, in the peer-reviewed journal Nutrients. The study shows that early supplementation with this strain during the first three months of life is associated with a markedly lower prevalence of functional abdominal pain (FAP)* at age ten. This follow-up builds on BioGaia's original randomized, controlled trial, which demonstrated that L. reuteri Protectis[Ò][ ] reduced symptoms of functional gastrointestinal...

BioGaia exercises the option to acquire the remaining 20 percent of the shares in Nutraceutics, the parent company to BioGaia's exclusive distributor of BioGaia's own products in the USA. BioGaia AB (publ) ("BioGaia") announced on December 30, 2021 that BioGaia, through its American subsidiary BioGaia Biologics Inc, had entered into an agreement to acquire all the shares in Nutraceutics Corporation ("Nutraceutics"). Nutraceutics owns all the shares in BioGaia USA which is the exclusive distributor of products under BioGaia's own brands in the USA. In accordance with what was...

BioGaia AB (NASDAQ: BIOG) has signed a renewed distribution agreement with Ewopharma. The extended agreement reinforces the companies' successful collaboration to date and reflects a shared ambition to further accelerate growth across the European region. Ewopharma is a pharmaceutical marketing organization and commercialization partner active in Central Eastern Europe and Switzerland, with expertise spanning prescription medicines, OTC products, and Consumer Health. Under the new agreement, Ewopharma will distribute a broad range of BioGaia's product portfolio in more than 15...

FOURTH QUARTER 2025 (Figures in parentheses refer to the corresponding period last year, unless otherwise specified.) Net sales amounted to SEK 440.6 million (364.8), an increase of SEK 75.7 million, an organic sales increase of 32% (21% including foreign exchange effects). Net sales in the Pediatrics segment amounted to SEK 331.5 million (270.3), an organic sales increase of 34% (23% including foreign exchange effects). Net sales in the Adult Health segment amounted to SEK 106.6 million (91.7), an organic sales increase of 27% (16% including foreign exchange effects). Operating...

(Figures in the brackets refer to the same period the previous year) During the fourth quarter of 2025, BioGaia's sales were positively affected by quarterly variations for individual orders of approximately SEK 35 million. For the fourth quarter, sales are preliminarily estimated at SEK 441 million (365), an increase of 21% (excluding foreign exchange effects, 32%). The operating profit for the fourth quarter is preliminarily estimated at SEK 121 million (103), an increase of 17% and an operating margin of 27% (28%). BioGaia publishes the interim report for the fourth quarter 2025...

BioGaia's (NASDAQ: BIOG) financial report for the fourth quarter of 2025 will be published at approximately 8:00 AM CET on February 12, 2026. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website (https://www.biogaiagroup.com/investors/financial-reports/). CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CET. To join the audiocast with teleconference and ask a...

Often considered as our “second brain”, the human gut and its resident microbiota play a crucial bidirectional role communicating the brain (central nervous system) with the gut (enteric nervous system), in what is called the microbiota-gut-brain axis. Researchers of University of Gothenburg and BioGaia AB (NASDAQ: BIOG) have identified that specific bacteria present in the gut can produce an important bioactive substance of the microbiota-gut-brain axis: serotonin. Serotonin is best known as a neurotransmitter in the brain, but over 90 percent of the body's serotonin is found in the...

THIRD QUARTER 2025 Net sales amounted to SEK 326.6 million (304.0), an increase of SEK 22.7 million, or an increase of 7% (excluding foreign exchange effects an increase of 14%). Net sales in the Pediatrics segment amounted to SEK 242.6 million (225.8), an increase of 7% (excluding foreign exchange effects an increase of 14%). Net sales in the Adult Health segment amounted to SEK 81.6 million (76.6), an increase of 6% (excluding foreign exchange effects an increase of 13%). Operating expenses amounted to SEK 156.5 million (180.9), a decrease of SEK 24.4 million (13%). Operating...

We are proud to announce that the scientific rationale and identification of our newly patented strain, Limosilactobacillus reuteri BG-R46®, has been published in the prestigious journal, Beneficial Microbes. This next-generation strain will be featured in our upcoming baby drops product. Developed by BioGaia AB (NASDAQ: BIOG) and a research team at the Swedish University of Agricultural Sciences in Uppsala, led by Prof. Stefan Roos, who also oversees BioGaia's preclinical studies. BG-R46® is an evolved derivative of L. reuteri DSM 17938, obtained through selective exposure to bile, a...